Get Live Data

Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

  2. Share Prices
  3. Hutchmed Share Price
  4. Hutchmed Share News
  5. DIRECTOR DEALINGS: Hutchison China Chairman Buys 25,000 Shares

Pin to quick picksHutchmed Share News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Hutchison China Chairman Buys 25,000 Shares

Mon, 13th Apr 2015 08:46

LONDON (Alliance News) - Hutchison China MediTech Limited Monday said Chairman Simon To bought 25,000 shares at a price of GBP14.215 per share Friday.

Following this transaction, To is beneficially interested in 152,000 shares, representing approximately 0.29% of the current issued share capital. To has purchased 108,000 shares since March 30.

Shares in the healthcare group were up 5.8% at 1,517.69 pence Monday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
20 Jan 2022 11:03

Hutchmed begins phase one study for potential tumour treatment

Hutchmed begins phase one study for potential tumour treatment

Read more
13 Jan 2022 09:10

TOP NEWS: Retailer ASOS now to be seen on London Main Market

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Read more
12 Jan 2022 11:37

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Hutchmed gains breakthrough therapy designation in China for HMPL-523

Read more
10 Jan 2022 09:23

Hutchmed begins phase one study for potential cancer treatment

Hutchmed begins phase one study for potential cancer treatment

Read more
6 Dec 2021 10:44

Hutchmed completes patient enrolment for cancer drug study

Hutchmed completes patient enrolment for cancer drug study

Read more
3 Dec 2021 13:23

Two Hutchmed drugs included in China's 2022 reimbursement list

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.

Read more
3 Dec 2021 09:54

Two Hutchmed drugs included on China's state approved medicines list

Two Hutchmed drugs included on China's state approved medicines list

Read more
24 Nov 2021 11:35

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Hutchmed China shares rise on Orphathys and Tagrisso Phase 3 study

Read more
1 Nov 2021 09:14

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

TOP NEWS: Astra transfers drug rights to Covis in USD270 million deal

Read more
28 Oct 2021 21:59

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

IN BRIEF: Hutchmed begins phase 3 trial of thrombocytopenia drug

Read more
29 Sep 2021 11:08

Hutchmed China sells joint venture stake for USD169 million

Hutchmed China sells joint venture stake for USD169 million

Read more
21 Sep 2021 10:51

Hutchmed starts drug combination trial for neuroendocrine tumours

Hutchmed starts drug combination trial for neuroendocrine tumours

Read more
20 Sep 2021 09:09

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Hutchmed starts Japan trial for surufatinib in neuroendocrine tumors

Read more
13 Sep 2021 10:22

Hutchmed China's amdizalisib secures breakthrough therapy designation

Hutchmed China's amdizalisib secures breakthrough therapy designation

Read more
8 Sep 2021 13:49

Hutchmed, Astra launch drug combination trial to treat lung cancer

Hutchmed, Astra launch drug combination trial to treat lung cancer

Read more
456789101112

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.